home / stock / nltx / nltx news

NLTX News and Press, Neoleukin Therapeutics Inc. From 01/07/21

Stock Information
Company Name: Neoleukin Therapeutics Inc.
Stock Symbol: NLTX
Market: NYSE
Menu
NLTX NLTX Quote NLTX Short NLTX News NLTX Articles NLTX Message Board
Get NLTX Alerts

News, Short Squeeze, Breakout and More Instantly...
NLTX - Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
NLTX - BABA, FUBO, GEVO and NLTX among midday movers

Gainers: Air T (AIRT) +156%.FAT Brands (FAT) +85%.Addex Therapeutics (ADXN) +72%.Senseonics Holdings (SENS) +57%.SIFCO Industries (SIF) +45%.Gevo (GEVO) +44%.Neoleukin Therapeutics (NLTX) +42%.Avinger (AVGR) +41%.IZEA Worldwide (IZEA) +23%.Harvest Capital Credit (HCAP) +20%.Losers: Jagua...

NLTX - Avinger, Neoleukin Therapeutics leads healthcare gainers; Jaguar Health, Ocugen among major losers

Gainers: Avinger (AVGR) +71%, Neoleukin Therapeutics (NLTX) +33%, Ampio Pharmaceuticals (AMPE) +25%, Odonate Therapeutics (ODT) +14%, INmune Bio (INMB) +9%.Losers: Jaguar Health (JAGX) -29%, Ocugen (OCGN) -23%, Second Sight Medical Produc...

NLTX - Neoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising Technology

Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-protein design. Neoleukin is developing one clinical therapeutic, NL-201 which is a...
NLTX - Neoleukin files U.S. trial application for early-stage solid tumor study with its lead protein immunotherapy Candidate

Neoleukin Therapeutics ([[NLTX]] +0.4%) has submitted an Investigational New Drug ((IND)) application with the FDA to initiate a Phase 1 study its lead immunotherapeutic candidate, NL-201. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL...

NLTX - Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational ...

NLTX - Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
NLTX - Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...

NLTX - Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020)

- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation - SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical compan...

NLTX - Neoleukin Therapeutics EPS beats by $0.19

Neoleukin Therapeutics (NLTX): Q3 GAAP EPS of -$0.04 beats by $0.19.Cash and cash equivalents of $201.2MPress Release For further details see: Neoleukin Therapeutics EPS beats by $0.19

Previous 10 Next 10